Tamoxifen oral liquid - Rosemont Pharmaceuticals

Drug Profile

Tamoxifen oral liquid - Rosemont Pharmaceuticals

Alternative Names: Soltamox; Tamoxifen citrate; Tamoxifen oral liquid solution - Rosemont Pharmaceuticals

Latest Information Update: 04 Jul 2016

Price : $50

At a glance

  • Originator Rosemont Pharmaceuticals Ltd; University of Birmingham
  • Developer Rosemont Pharmaceuticals Ltd
  • Class Antineoplastics; Chemopreventatives; Dimethylamines; Infertility therapies; Phenyl ethers; Small molecules; Stilbenes
  • Mechanism of Action Estrogen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 06 Jan 2015 DARA Biosciences receives product and establishment fee waiver from the FDA
  • 29 Oct 2014 DARA BioSciences files a petition with US FDA for a label update for Tamoxifen oral liquid as an adjuvant therapy for breast cancer, from five to ten years .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top